FR19C1028I1 - - Google Patents

Info

Publication number
FR19C1028I1
FR19C1028I1 FR19C1028C FR19C1028I1 FR 19C1028 I1 FR19C1028 I1 FR 19C1028I1 FR 19C1028 C FR19C1028 C FR 19C1028C FR 19C1028 I1 FR19C1028 I1 FR 19C1028I1
Authority
FR
France
Prior art keywords
ccr4
human
antibody
extracellular region
specifically reacts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR19C1028I1 publication Critical patent/FR19C1028I1/fr
Application granted granted Critical
Publication of FR19C1028I2 publication Critical patent/FR19C1028I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Abstract

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
FR19C1028C 2001-08-31 2019-04-19 ANTIBODIES GRAFTED WITH HUMAN CDRs AND FRAGMENTS OF THESE ANTIBODIES Active FR19C1028I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001265144 2001-08-31
PCT/JP2002/008828 WO2003018635A1 (en) 2001-08-31 2002-08-30 Human cdr-grafted antibodies and antibody fragments thereof

Publications (2)

Publication Number Publication Date
FR19C1028I1 true FR19C1028I1 (en) 2019-05-17
FR19C1028I2 FR19C1028I2 (en) 2021-02-19

Family

ID=19091652

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1028C Active FR19C1028I2 (en) 2001-08-31 2019-04-19 ANTIBODIES GRAFTED WITH HUMAN CDRs AND FRAGMENTS OF THESE ANTIBODIES

Country Status (23)

Country Link
US (8) US7504104B2 (en)
EP (1) EP1449850B9 (en)
JP (1) JP4052515B2 (en)
KR (1) KR100959248B1 (en)
CN (1) CN100430420C (en)
AT (1) ATE490277T1 (en)
AU (1) AU2002338015B8 (en)
BE (1) BE2019C006I2 (en)
BR (1) BRPI0212266B8 (en)
CA (1) CA2458627C (en)
CO (1) CO5560582A2 (en)
CY (2) CY1111193T1 (en)
DE (1) DE60238503D1 (en)
DK (1) DK1449850T3 (en)
ES (1) ES2356190T3 (en)
FR (1) FR19C1028I2 (en)
HK (1) HK1073851A1 (en)
LU (1) LUC00116I2 (en)
MX (1) MXPA04001894A (en)
NL (1) NL300985I2 (en)
NO (1) NO334858B1 (en)
PT (1) PT1449850E (en)
WO (1) WO2003018635A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270148A3 (en) * 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2401491C (en) 2000-03-03 2011-07-05 Kyowa Hakko Kogyo Co., Ltd. Ccr4-binding antibody and diagnostic and therapeutic uses thereof
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2003211550A1 (en) * 2002-02-28 2003-09-09 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for interstitial pneumonia
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
EP3006463A1 (en) 2003-10-01 2016-04-13 Kyowa Hakko Kirin Co., Ltd. Method for stabilizing antibody and stabilized solution-type antibody preparation
JPWO2005035582A1 (en) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 Antibody composition that specifically binds to CCR4
EP1702625B1 (en) 2003-12-04 2010-11-03 Kyowa Hakko Kirin Co., Ltd. Medicine containing genetically modified antibody against chemokine receptor ccr4
PL1703893T3 (en) * 2003-12-23 2012-09-28 Genentech Inc Novel anti-il 13 antibodies and uses thereof
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
US20070172476A1 (en) * 2005-07-28 2007-07-26 Kyowa Hakko Kogyo Co., Ltd. Method of treating B-cell neoplasms or Hodgkin's lymphoma
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US8962806B2 (en) * 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
JP5552630B2 (en) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Medicament for treating or preventing HTLV-I related myelopathy and method for testing the effect of antibody therapy on patients with HTLV-I related myelopathy
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
ES2502541T3 (en) * 2009-09-10 2014-10-03 Kyowa Hakko Kirin Co., Ltd. Medication that includes an antibody composition specifically bound to human CC chemokine receptor 4 (CCR4)
CN102863533B (en) * 2010-06-21 2013-12-11 中国科学技术大学 Method for humanized reform for antibody
EA201370030A1 (en) 2010-08-10 2013-06-28 Амген Инк. BIFUNCTIONAL QUANTITATIVE IN VITRO ANALYSIS OF BINDING TARGETS FOR DETECTING NEUTRALIZING ANTIBODIES TO TARGET ANTIBODIES
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
JP6005657B2 (en) 2010-12-16 2016-10-12 ジェネンテック， インコーポレイテッド Diagnosis and treatment related to TH2 inhibition
ES2758884T3 (en) 2011-06-24 2020-05-06 Stephen D Gillies Immunoglobulin fusion proteins via light chain and methods of using them
MX365592B (en) 2012-07-06 2019-06-07 Univ School St Marianna Medicine Therapeutic method and remedy for htlv-1-associated myelopathy patients.
JP6546178B2 (en) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド Compositions and methods for detecting and quantifying host cell proteins and recombinant polypeptide products in cell lines
MY176026A (en) 2013-09-13 2020-07-22 Genentech Inc Methods and composions comprising purified recombinant polypeptides
JP2017517506A (en) 2014-05-21 2017-06-29 ファイザー・インコーポレイテッド Combination of anti-CCR4 antibody and 4-1BB agonist for treating cancer
US20180271861A1 (en) 2015-07-14 2018-09-27 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
RU2020122822A (en) 2017-12-12 2022-01-13 Макродженикс, Инк. BISPECIFIC CD16 BINDING MOLECULES AND THEIR USE IN THE TREATMENT OF DISEASES
CN108250290B (en) 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 N-terminal recombinant protein of CCR4 and application thereof
CN116731186B (en) * 2023-07-07 2023-12-26 武汉爱博泰克生物科技有限公司 Anti-human IgG-Fc rabbit monoclonal antibody and preparation method thereof, polynucleotide molecule, expression vector and host cell

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (en) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Il-5 production-inhibiting agent
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
WO1997010354A1 (en) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
EP1030662B1 (en) 1997-11-12 2006-08-02 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
WO2000000219A1 (en) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Remedies for hypercalcemic crisis
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EP1050307A1 (en) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
CA2401491C (en) * 2000-03-03 2011-07-05 Kyowa Hakko Kogyo Co., Ltd. Ccr4-binding antibody and diagnostic and therapeutic uses thereof
EP1702625B1 (en) * 2003-12-04 2010-11-03 Kyowa Hakko Kirin Co., Ltd. Medicine containing genetically modified antibody against chemokine receptor ccr4

Also Published As

Publication number Publication date
DK1449850T3 (en) 2011-02-14
JPWO2003018635A1 (en) 2004-12-09
US20110059524A1 (en) 2011-03-10
JP4052515B2 (en) 2008-02-27
BE2019C006I2 (en) 2021-11-22
NO20040976L (en) 2004-06-01
ATE490277T1 (en) 2010-12-15
US7504104B2 (en) 2009-03-17
US8900584B2 (en) 2014-12-02
CY2019022I1 (en) 2019-11-27
NL300985I1 (en) 2019-05-08
US20120177643A1 (en) 2012-07-12
US10590203B2 (en) 2020-03-17
CA2458627A1 (en) 2003-03-06
US7842797B2 (en) 2010-11-30
LUC00116I1 (en) 2019-05-02
WO2003018635A1 (en) 2003-03-06
EP1449850B1 (en) 2010-12-01
US20150315285A1 (en) 2015-11-05
PT1449850E (en) 2011-02-02
US20180030146A1 (en) 2018-02-01
MXPA04001894A (en) 2005-09-08
NO334858B1 (en) 2014-06-23
US20090227012A1 (en) 2009-09-10
KR100959248B1 (en) 2010-05-26
KR20040044492A (en) 2004-05-28
US10131711B2 (en) 2018-11-20
BR0212266A (en) 2004-10-19
DE60238503D1 (en) 2011-01-13
US20030175273A1 (en) 2003-09-18
BRPI0212266B8 (en) 2021-05-25
US8143058B2 (en) 2012-03-27
CN100430420C (en) 2008-11-05
EP1449850B9 (en) 2011-05-11
LUC00116I2 (en) 2019-12-27
CA2458627C (en) 2013-09-10
US9051371B2 (en) 2015-06-09
CY1111193T1 (en) 2015-06-11
CO5560582A2 (en) 2005-09-30
EP1449850A4 (en) 2005-08-10
FR19C1028I2 (en) 2021-02-19
ES2356190T3 (en) 2011-04-05
US20130273038A1 (en) 2013-10-17
CN1575303A (en) 2005-02-02
NL300985I2 (en) 2019-11-21
HK1073851A1 (en) 2005-10-21
AU2002338015B2 (en) 2008-02-07
AU2002338015B8 (en) 2008-03-20
EP1449850A1 (en) 2004-08-25
CY2019022I2 (en) 2019-11-27
BRPI0212266B1 (en) 2020-05-05
US20140186349A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
NL300985I1 (en) mogamulizumab
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
EP1238985A4 (en) Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3
HUP0303952A2 (en) Remedies for infant chronic arthritis-relating diseases
NO332893B1 (en) Use of antibody for the preparation of drug for use in CVP chemotherapy
TW224428B (en)
TR200001891T2 (en) ASPB28- Human insulin and its use.
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
WO2003009815A3 (en) Compositions and methods for modulating blood-brain barrier transport
MXPA05005315A (en) Medical devices incorporating deuterated rapamycin for controlled delivery thereof.
AU2002231691A1 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
BR0308904A (en) Method of treatment of gastroparesis and use of a glp-1 compound
EP1702625A4 (en) Medicine containing genetically modified antibody against chemokine receptor ccr4
ATE327772T1 (en) THERAPEUTIC AND DIAGNOSTIC LIGAND SYSTEMS WITH TRANSPORT MOLECULE BINDING PROPERTIES AND MEDICINAL PRODUCTS CONTAINING SAME
AU1951195A (en) Combinations of thrombolytically active proteins and anticoagulants, and uses thereof
HU9301253D0 (en) Medical preparative applicable for treatment of enlarged time of coagulation
MXPA04002510A (en) Combination of selected opioids with muscarine antagonists for treating urinary incontinence.
ES2080037T1 (en) TOPIC USE MEDICINE WITH HEALING ACTIVITY.
AU2003290015A1 (en) Mastitis treatment
ATE271852T1 (en) IMPROVED INHALATION PREPARATIONS
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents
TR200202110T2 (en) "5 - [{6- (2-Fluorine benzyl) oxy-2-naphthyl} methyl] -2,4-thiazolidine dion crystals"
WO1999064065A3 (en) Tumour therapy and imaging
WO2002082077A3 (en) Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes